{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:42:22Z","timestamp":1790703742891,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-025-01264-2","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:21:09Z","timestamp":1759490469000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Harm reduction practises for users of psychedelic drugs: a scoping review"],"prefix":"10.1186","volume":"22","author":[{"given":"Carissa","family":"Dutton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"North","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ylona","family":"Chun Tie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Skeffington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"1264_CR1","unstructured":"The National Household Drug Strategy Survey 2022\u20132023 [https:\/\/www.aihw.gov.au\/about-our-data\/our-data-collections\/national-drug-strategy-household-survey\/2022-ndshs]"},{"key":"1264_CR2","unstructured":"Winstock ARML, Zhupparris A, Davies E, Puljevic C, Kuypers KPC, Ferris JA and Barrat MJ, Global Drug Survey 2022: 7 Year Drug Trend Report, 2022."},{"key":"1264_CR3","unstructured":"Drug Misuse in England and Wales: Year ending March. 2023. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/crimeandjustice\/articles\/drugmisuseinenglandandwales\/yearendingmarch2023"},{"key":"1264_CR4","unstructured":"Beau Kilmer MP, Rajeev R, Rhianna CR, Ben S, Keytin P. Considering alternatives to psychedelic drug prohibition, 2024."},{"key":"1264_CR5","unstructured":"Notice of final decision to amend (or not amend) the current Poisons Standard- June 2022 ACMS #38- Psilocybine and MDMA. https:\/\/www.tga.gov.au\/resources\/publication\/scheduling-decisions-final\/notice-final-decision-amend-or-not-amend-current-poisons-standard-june-2022-acms-38-psilocybine-and-mdma"},{"key":"1264_CR6","doi-asserted-by":"publisher","first-page":"e43850","DOI":"10.2196\/43850","volume":"7","author":"G Danias","year":"2023","unstructured":"Danias G, Appel J. Public interest in psilocybin and psychedelic therapy in the context of the COVID-19 pandemic: google trends analysis. JMIR Form Res. 2023;7:e43850.","journal-title":"JMIR Form Res"},{"key":"1264_CR7","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1007\/s00213-021-06049-6","volume":"239","author":"D Bender","year":"2022","unstructured":"Bender D, Hellerstein DJ. Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research. Psychopharmacology. 2022;239:1907\u201332.","journal-title":"Psychopharmacology"},{"key":"1264_CR8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/02698811211069100","volume":"36","author":"AK Schlag","year":"2022","unstructured":"Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: from anecdotes and misinformation to systematic science. J Psychopharmacol. 2022;36:258\u201372.","journal-title":"J Psychopharmacol"},{"key":"1264_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","volume":"101","author":"DE Nichols","year":"2004","unstructured":"Nichols DE. Hallucinogens. Pharmacol Ther. 2004;101:131\u201381.","journal-title":"Pharmacol Ther"},{"key":"1264_CR10","doi-asserted-by":"publisher","first-page":"1040217","DOI":"10.3389\/fpsyt.2022.1040217","volume":"13","author":"CA MacCallum","year":"2022","unstructured":"MacCallum CA, Lo LA, Pistawka CA, Deol JK. Therapeutic use of psilocybin: practical considerations for dosing and administration. Front Psych. 2022;13:1040217.","journal-title":"Front Psych"},{"key":"1264_CR11","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/j.1360-0443.2004.00744.x","volume":"99","author":"RS Gable","year":"2004","unstructured":"Gable RS. Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction. 2004;99:686\u201396.","journal-title":"Addiction"},{"key":"1264_CR12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"MW Johnson","year":"2008","unstructured":"Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22:603\u201320.","journal-title":"J Psychopharmacol"},{"key":"1264_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187:268\u201383.","journal-title":"Psychopharmacology"},{"key":"1264_CR14","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387:1637\u201348.","journal-title":"N Engl J Med"},{"key":"1264_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/16066350500053562","volume":"13","author":"P Dalgarno","year":"2005","unstructured":"Dalgarno P, Shewan D. Reducing the risks of drug use: the case for set and setting. Addict Res Theory. 2005;13:259\u201365.","journal-title":"Addict Res Theory"},{"key":"1264_CR16","doi-asserted-by":"publisher","first-page":"887255","DOI":"10.3389\/fpsyg.2022.887255","volume":"13","author":"M Cavarra","year":"2022","unstructured":"Cavarra M, Falzone A, Ramaekers JG, Kuypers KPC, Mento C. Psychedelic-assisted psychotherapy\u2014a systematic review of associated psychological interventions. Front Psychol. 2022;13:887255.","journal-title":"Front Psychol"},{"key":"1264_CR17","doi-asserted-by":"publisher","first-page":"e0229067","DOI":"10.1371\/journal.pone.0229067","volume":"15","author":"B Bienemann","year":"2020","unstructured":"Bienemann B, Ruschel NS, Campos ML, Negreiros MA, Mograbi DC. Self-reported negative outcomes of psilocybin users: a quantitative textual analysis. PLoS One. 2020;15:e0229067.","journal-title":"PLoS One"},{"key":"1264_CR18","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/0269881116662634","volume":"30","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, Griffiths RR. Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol. 2016;30:1268\u201378.","journal-title":"J Psychopharmacol"},{"key":"1264_CR19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12954-023-00908-5","volume":"20","author":"Y Milshteyn","year":"2023","unstructured":"Milshteyn Y, Bensimon M. Exploring the subjective experience of rave party participants in Israel who consume psychedelic drugs: a qualitative inquiry. Harm Reduct J. 2023;20:176.","journal-title":"Harm Reduct J"},{"key":"1264_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jad.2023.01.073","volume":"326","author":"O Simonsson","year":"2023","unstructured":"Simonsson O, Hendricks PS, Chambers R, Osika W, Goldberg SB. Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics. J Affect Disord. 2023;326:105\u201310.","journal-title":"J Affect Disord"},{"key":"1264_CR21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1108\/DAT-03-2020-0016","volume":"21","author":"J Pestana","year":"2021","unstructured":"Pestana J, Beccaria F, Petrilli E. Psychedelic substance use in the Reddit psychonaut community. A qualitative study on motives and modalities. Drugs Alcohol Today. 2021;21:112\u201323.","journal-title":"Drugs Alcohol Today"},{"key":"1264_CR22","doi-asserted-by":"publisher","first-page":"1199642","DOI":"10.3389\/fpsyt.2023.1199642","volume":"14","author":"SM Nayak","year":"2023","unstructured":"Nayak SM, Jackson H, Sepeda ND, Mathai DS, So S, Yaffe A, Zaki H, Brasher TJ, Lowe MX, Jolly DR. Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey. Front Psych. 2023;14:1199642.","journal-title":"Front Psych"},{"key":"1264_CR23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1037\/cns0000283","volume":"10","author":"BS-BL Fauvel","year":"2023","unstructured":"Fauvel BS-BL, Piolino P. Changes in self rumination and self compassion meditate the effect of pscychedelic expereinces on decreases in depression, anxiety and stress. Psychol Conscious Theory Res Practice. 2023;10:88\u2013102.","journal-title":"Psychol Conscious Theory Res Practice"},{"key":"1264_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3109\/10826089909035632","volume":"34","author":"D Riley","year":"1999","unstructured":"Riley D, Sawka E, Conley P, Hewitt D, Mitic W, Poulin C, Room R, Single E, Topp J. Harm reduction: concepts and practice. A policy discussion paper. Subst Use Misuse. 1999;34:9\u201324.","journal-title":"Subst Use Misuse"},{"key":"1264_CR25","unstructured":"Care AG-DoHaA. National drug strategy. Comnonwealth of Australia, 2017."},{"key":"1264_CR26","doi-asserted-by":"publisher","first-page":"645246","DOI":"10.3389\/fpsyg.2021.645246","volume":"12","author":"I Gorman","year":"2021","unstructured":"Gorman I, Nielson EM, Molinar A, Cassidy K, Sabbagh J. Psychedelic harm reduction and integration: a transtheoretical model for clinical practice. Front Psychol. 2021;12:645246.","journal-title":"Front Psychol"},{"key":"1264_CR27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12954-021-00489-1","volume":"18","author":"B Pilecki","year":"2021","unstructured":"Pilecki B, Luoma JB, Bathje GJ, Rhea J, Narloch VF. Ethical and legal issues in psychedelic harm reduction and integration therapy. Harm Reduct J. 2021;18:40.","journal-title":"Harm Reduct J"},{"key":"1264_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8:19\u201332.","journal-title":"Int J Soc Res Methodol"},{"key":"1264_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12874-018-0611-x","volume":"18","author":"Z Munn","year":"2018","unstructured":"Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18:143.","journal-title":"BMC Med Res Methodol"},{"key":"1264_CR30","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169:467\u201373.","journal-title":"Ann Intern Med"},{"key":"1264_CR31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12954-023-00845-3","volume":"20","author":"H Bonny-Noach","year":"2023","unstructured":"Bonny-Noach H, Shapira B, Baumol P, Tadmor N, Rosca P, Shoshan S, Harel-Fisch Y, Caduri A. Substance use, harm reduction attitudes and behaviors among attendees of nature rave parties in Israel. Harm Reduct J. 2023;20:108.","journal-title":"Harm Reduct J"},{"key":"1264_CR32","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1080\/02791072.2023.2201263","volume":"55","author":"DJ Kruger","year":"2023","unstructured":"Kruger DJ, Enghoff O, Herberholz M, Barron J, Boehnke KF. \u201cHow do I learn more about this?\u201d: Utilization and trust of psychedelic information sources among people naturalistically using psychedelics. J Psychoact Drugs. 2023;55:631\u20139.","journal-title":"J Psychoact Drugs"},{"key":"1264_CR33","doi-asserted-by":"crossref","unstructured":"Kender-Jeziorska I. Patterns of recreational drug use and harm reduction strategies among women at music festivals: the case of Hungary and Poland. In: The impact of global drug policy on women: shifting the needle. Emerald Group Publishing Ltd., 2020: pp 201\u201311.","DOI":"10.1108\/978-1-83982-882-920200028"},{"key":"1264_CR34","doi-asserted-by":"publisher","first-page":"623985","DOI":"10.3389\/fphar.2021.623985","volume":"12","author":"H Kettner","year":"2021","unstructured":"Kettner H, Rosas FE, Timmermann C, K\u00e4rtner L, Carhart-Harris RL, roseman L. Psychedelic communitas: intersubjective experience during psychedelic group sessions predicts enduring changes in psychological wellbeing and social connectedness. Front Pharmacol. 2021;12:623985.","journal-title":"Front Pharmacol"},{"key":"1264_CR35","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1038\/s41598-024-54642-4","volume":"14","author":"RG McAlpine","year":"2024","unstructured":"McAlpine RG, Sacchet MD, Simonsson O, Khan M, Krajnovic K, Morometescu L, Kamboj SK. Development of a digital intervention for psychedelic preparation (DIPP). Sci Rep. 2024;14:4072.","journal-title":"Sci Rep"},{"key":"1264_CR36","doi-asserted-by":"publisher","first-page":"102600","DOI":"10.1016\/j.drugpo.2019.11.008","volume":"75","author":"T Lea","year":"2020","unstructured":"Lea T, Amada N, Jungaberle H, Schecke H, Klein M. Microdosing psychedelics: motivations, subjective effects and harm reduction. Int J Drug Pol. 2020;75:102600.","journal-title":"Int J Drug Pol"},{"key":"1264_CR37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12954-022-00662-0","volume":"19","author":"M Palmer","year":"2022","unstructured":"Palmer M, Maynard OM. Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience. Harm Reduct J. 2022;19:81.","journal-title":"Harm Reduct J"},{"key":"1264_CR38","doi-asserted-by":"publisher","first-page":"e0293349","DOI":"10.1371\/journal.pone.0293349","volume":"18","author":"J Evans","year":"2023","unstructured":"Evans J, Robinson OC, Argyri EK, Suseelan S, Murphy-Beiner A, McAlpine R, Luke D, Michelle K, Prideaux E. Extended difficulties following the use of psychedelic drugs: a mixed methods study. PLoS One. 2023;18:e0293349.","journal-title":"PLoS One"},{"key":"1264_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugpo.2022.103945","volume":"112","author":"S Holm","year":"2023","unstructured":"Holm S, Petersen MA, Enghoff O, Hesse M. Psychedelic discourses: a qualitative study of discussions in a Danish online forum. Int J Drug Pol. 2023;112:1\u20139.","journal-title":"Int J Drug Pol"},{"key":"1264_CR40","doi-asserted-by":"publisher","first-page":"269881124125483","DOI":"10.1177\/02698811241254837","volume":"38","author":"L Baxter","year":"2024","unstructured":"Baxter L, Puljevic C, Piatkowski T, Ferris J, Davies EL, Barratt MJ, Winstock A. Tripping into the unknown: Exploring the experiences of first-time LSD users through global drug survey insights. J Psychopharmacol. 2024;38:2698811241254837.","journal-title":"J Psychopharmacol"},{"key":"1264_CR41","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1177\/00914509221121420","volume":"49","author":"LB Engel","year":"2022","unstructured":"Engel LB, Thal SB, Bright SJ. Psychedelic forum member preferences for carer experience and consumption behavior: Can \u201ctrip sitters\u201d help inform psychedelic harm reduction services? Contemp Drug Probl Interdiscip Q. 2022;49:356\u201368.","journal-title":"Contemp Drug Probl Interdiscip Q"},{"key":"1264_CR42","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.drugpo.2007.07.003","volume":"19","author":"C Duff","year":"2008","unstructured":"Duff C. The pleasure in context. Int J Drug Pol. 2008;19:384\u201392.","journal-title":"Int J Drug Pol"},{"key":"1264_CR43","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/02791072.2022.2129885","volume":"55","author":"AM McCartney","year":"2023","unstructured":"McCartney AM, McGovern HT, De Foe A. Predictors of psychedelic experience: a thematic analysis. J Psychoact Drugs. 2023;55:411\u20139.","journal-title":"J Psychoact Drugs"},{"key":"1264_CR44","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/02791072.2022.2039815","volume":"55","author":"KO St Arnaud","year":"2023","unstructured":"St Arnaud KO, Sharpe D. Contextual parameters associated with positive and negative mental health in recreational psychedelic users. J Psychoact Drugs. 2023;55:30\u20139.","journal-title":"J Psychoact Drugs"},{"issue":"4","key":"1264_CR45","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1108\/DAT-10-2018-0052","volume":"19","author":"S Rolando","year":"2019","unstructured":"Rolando S, Beccaria F. The junkie abuses, the psychonaut learns: a qualitative analysis of an online drug forum community. Drugs Alcohol Today. 2019;19(4):282\u201394. https:\/\/doi.org\/10.1108\/DAT-10-2018-0052.","journal-title":"Drugs Alcohol Today."},{"key":"1264_CR46","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/02791072.2022.2054746","volume":"55","author":"L Shaw","year":"2023","unstructured":"Shaw L, Rea K, Lachowsky NJ, Roth EA. Magic mushroom use: a qualitative interview study of post-trip impacts and strategies for optimizing experiences. J Psychoact Drugs. 2023;55:151\u20138.","journal-title":"J Psychoact Drugs"},{"key":"1264_CR47","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.drugpo.2017.07.017","volume":"49","author":"F B\u00f8hling","year":"2017","unstructured":"B\u00f8hling F. Psychedelic pleasures: an affective understanding of the joys of tripping. Int J Drug Pol. 2017;49:133\u201343.","journal-title":"Int J Drug Pol"},{"key":"1264_CR48","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1111\/dar.13480","volume":"41","author":"LA Basedow","year":"2022","unstructured":"Basedow LA, Kuitunen-Paul S. Motives for the use of serotonergic psychedelics: a systematic review. Drug Alcohol Rev. 2022;41:1391\u2013403.","journal-title":"Drug Alcohol Rev"},{"key":"1264_CR49","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2174\/1874473708666150107115515","volume":"7","author":"MC Carvalho","year":"2014","unstructured":"Carvalho MC, de Sousa MP, Frango P, Dias P, Carvalho J, Rodrigues M, Rodrigues T. Crisis intervention related to the use of psychoactive substances in recreational settings\u2013evaluating the Kosmicare Project at Boom Festival. Curr Drug Abuse Rev. 2014;7:81\u2013100.","journal-title":"Curr Drug Abuse Rev"},{"key":"1264_CR50","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1177\/002204260203200207","volume":"32","author":"S Prepeliczay","year":"2002","unstructured":"Prepeliczay S. Socio-cultural and psychological aspects of contemporary LSD use in Germany. J Drug Issues. 2002;32:431\u201358.","journal-title":"J Drug Issues"},{"key":"1264_CR51","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/02791072.2020.1737763","volume":"52","author":"RL Lancelotta","year":"2020","unstructured":"Lancelotta RL, Davis AK. Use of benefit enhancement strategies among 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT) users: associations with mystical, challenging, and enduring effects. J Psychoact Drugs. 2020;52:273\u201381.","journal-title":"J Psychoact Drugs"},{"key":"1264_CR52","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40429-021-00385-5","volume":"8","author":"T Hirschfeld","year":"2021","unstructured":"Hirschfeld T, Smit-Rigter L, van der Gouwe D, Reiche S, St\u00f6ver H, Maji\u0107 T. Safer tripping: serotonergic psychedelics and drug checking. submission and detection rates, potential harms, and challenges for drug analysis. Curr Addict Rep. 2021;8:389\u201398.","journal-title":"Curr Addict Rep"},{"key":"1264_CR53","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/02698811231214060","volume":"38","author":"MN Mian","year":"2024","unstructured":"Mian MN, Altman BR, Low F, Earleywine M. Development of the protective strategies for psychedelics scale: a novel inventory to assess safety strategies in the context of psychedelics. J Psychopharmacol. 2024;38:101\u20139.","journal-title":"J Psychopharmacol"},{"key":"1264_CR54","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1556\/2054.2023.00261","volume":"7","author":"KJ Byrne","year":"2023","unstructured":"Byrne KJ, Lindsay S, Baker N, Schmutz C, Lewis B. In naturalistic psychedelic use, group use is common and acceptable. J Psychedelic Stud. 2023;7:100\u201313.","journal-title":"J Psychedelic Stud"},{"key":"1264_CR55","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/psymed.2022.0017","volume":"1","author":"MM Pleet","year":"2023","unstructured":"Pleet MM, White J, Zamaria JA, Yehuda R. Reducing the harms of nonclinical psychedelics use through a peer-support telephone helpline. Psychedelic Med. 2023;1:69\u201373.","journal-title":"Psychedelic Med"},{"key":"1264_CR56","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0269881118754710","volume":"32","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I, Kaelen M. Psychedelics and the essential importance of context. J Psychopharmacol. 2018;32:725\u201331.","journal-title":"J Psychopharmacol"},{"key":"1264_CR57","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1192\/bjp.185.3.196","volume":"185","author":"C Curran","year":"2004","unstructured":"Curran C, Byrappa N, McBride A. Stimulant psychosis: systematic review. Br J Psychiatry. 2004;185:196\u2013204.","journal-title":"Br J Psychiatry"},{"key":"1264_CR58","volume-title":"The psychedelic experience: a manual based on the tibetan book of the dead","author":"RM Timothy Leary","year":"1964","unstructured":"Timothy Leary RM, Richard A. The psychedelic experience: a manual based on the tibetan book of the dead. New York, NY: Citadel Press; 1964."},{"key":"1264_CR59","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1177\/02698811221127954","volume":"36","author":"SB Thal","year":"2022","unstructured":"Thal SB, Wieberneit M, Sharbanee JM, Skeffington PM, Baker P, Bruno R, Wenge T, Bright SJ. Therapeutic (Sub)stance: current practice and therapeutic conduct in preparatory sessions in substance-assisted psychotherapy\u2014a systematized review. J Psychopharmacol. 2022;36:1191\u2013207.","journal-title":"J Psychopharmacol"},{"key":"1264_CR60","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1477-7517-10-18","volume":"10","author":"L Moro","year":"2013","unstructured":"Moro L, Racz J. Online drug user-led harm reduction in Hungary: a review of \u201cDaath.\u201d Harm Reduct J. 2013;10:18.","journal-title":"Harm Reduct J"},{"key":"1264_CR61","doi-asserted-by":"publisher","first-page":"824077","DOI":"10.3389\/fpsyg.2022.824077","volume":"13","author":"GJ Bathje","year":"2022","unstructured":"Bathje GJ, Majeski E, Kudowor M. Psychedelic integration: An analysis of the concept and its practice. Front Psychol. 2022;13:824077.","journal-title":"Front Psychol"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01264-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01264-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01264-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:05:57Z","timestamp":1759493157000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-025-01264-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1264"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01264-2","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"7 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"158"}}